尊敬的投资者及分析师：
具备研发、生产及销售的一体化生物制药商——联康生物科技集团有限公司（股份代号：690），欣然为各位介绍2018年度本集团的重点回顾事件。
请点击此链接浏览公司简讯：690_联康集团2018年简讯.pdf
此外，请参考2018年下半年联康集团的重要进展：
联康集团全球首款全生物表达新药.pdf
联康集团口服抗糖尿病药阿卡波糖片获国家药品监督管理局正式受理.pdf
联康集团新药Uni-PTH获国家食品药品监督管理总局正式受理.pdf
联康集团与上海信忠医药签订 匹纳普 产品全国推广合作项目协议.pdf
Best Regards,
DLK Advisory Limited 金通策略有限公司 | www.dlkadvisory.com
Hong Kong Office:
Room 906, 9/F, Nan Fung Tower, 88 Connaught Road Central, Hong Kong 香港中環干諾道中88號南豐大廈9樓906室
T: +852 2857 7101 | F: +852 2857 7103
Taipei Office:
Room 1736, 17/F., No. 270, Sec. 4, Zhongxiao E. Rd., Da-an Dist., Taipei, Taiwan 臺北市大安區忠孝東路四段270號17樓1736室
T:+886 2 7707 0616
The information in this email and any attachment(s) is confidential and intended solely for the use of the individual to whom it is addressed. Any unauthorized use or dissemination is prohibited. If you are not the intended recipient, please notify the sender immediately and delete it from your system. E-mail transmission cannot be guaranteed to be secure or error-free. DLK Advisory Limited does not accept liability for any errors or omissions in the information of this email or any attachment(s).
If you do not want to receive this news alert, please click here to unsubscribe.
|